Effect of Buyi Xiaozheng Prescription on immune microenvironment in window period of chemotherapy for advanced ovarian cancer

DING Chenhuan; LI Jin; ZHANG Xu; LI He

doi:10.16305/j.1007-1334.2023.2211096

您当前的位置：

首页 >

文章列表页 >

Effect of Buyi Xiaozheng Prescription on immune microenvironment in window period of chemotherapy for advanced ovarian cancer

更新时间：2023-05-16

- Effect of Buyi Xiaozheng Prescription on immune microenvironment in window period of chemotherapy for advanced ovarian cancer
- Shanghai Journal of Traditional Chinese Medicine Vol. 57, Issue 5, Pages: 76-79(2023)
- 作者机构：
  
  1.上海交通大学医学院附属仁济医院（上海 200127）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2023.2211096
  CLC：
扫描看全文
丁忱欢,李瑾,张旭,等.补益消徵方对晚期卵巢癌患者化学疗法“窗口期”免疫微环境的影响[J].上海中医药杂志,2023,57(5):76-79.

DING Chenhuan,LI Jin,ZHANG Xu,et al.Effect of Buyi Xiaozheng Prescription on immune microenvironment in window period of chemotherapy for advanced ovarian cancer[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(5):76-79.
丁忱欢,李瑾,张旭,等.补益消徵方对晚期卵巢癌患者化学疗法“窗口期”免疫微环境的影响[J].上海中医药杂志,2023,57(5):76-79. DOI： 10.16305/j.1007-1334.2023.2211096.

DING Chenhuan,LI Jin,ZHANG Xu,et al.Effect of Buyi Xiaozheng Prescription on immune microenvironment in window period of chemotherapy for advanced ovarian cancer[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(5):76-79. DOI： 10.16305/j.1007-1334.2023.2211096.

摘要

目的,2,观察补益消徵方对晚期卵巢癌患者化学疗法（简称“化疗”）“窗口期”免疫微环境的影响及临床疗效。,方法,2,将60例晚期卵巢癌患者随机分为对照组和治疗组，每组30例，对照组采用常规治疗，治疗组在对照组治疗措施的基础上加用补益消徵方口服。比较两组CD3,+,T细胞、CD4,+,T细胞、CD8,+,T细胞、CD4,+,T细胞/CD8,+,T细胞、CD25,+,调节性T（Treg）细胞、自然杀伤（NK）细胞水平变化情况，并观察近期临床疗效。,结果,2,①试验过程中，治疗组脱落2例，对照组脱落3例，最终完成试验者55例，治疗组28例、对照组27例。②近期疗效比较，治疗组12个月治疗有效率为42.86%、肿瘤控制率为71.42%，分别优于对照组的33.33%和44.44%（,P,<,0.05）。③化疗后7 d与治疗前组内比较，两组CD3,+,T细胞、CD4,+,T细胞、CD8,+,T细胞、CD25,+,Treg细胞水平均明显降低（,P,<,0.05）；化疗后14 d、化疗后28 d组间比较，治疗组CD3,+,T细胞、CD4,+,T细胞、CD8,+,T细胞、CD25,+,Treg细胞水平高于对照组（,P,<,0.05）。④化疗后14 d与治疗前组内比较，两组NK细胞水平均下降（,P,<,0.05）；化疗后14 d、化疗后28 d组间比较，治疗组NK细胞水平高于对照组（,P,<,0.05）。,结论,2,补益消徵方能够有效抑制晚期卵巢癌的进展，并在化疗后的免疫“窗口期”起到正向调控T细胞、NK细胞的作用，使得化疗后患者体内的免疫抑制暂时逆转，为进一步的免疫治疗提供良好治疗环境。

Abstract

Objective,2,To study the effect of Buyi Xiaozheng Prescription （BXP） on the immune microenvironment in the window period of chemotherapy for advanced ovarian cancer， and to observe the clinical efficacy of BXP.,Methods,2,Sixty patients diagnosed with advanced ovarian cancer were randomly divided into a control group （,n,=30） and a treatment group （,n,=30）. The control group was given conventional chemotherapy， and the treatment group was given the conventional treatment measures of the control group together with the oral administration of BXP. The changes in the number and proportion of CD3,+,T， CD4,+,T， CD8,+,T， CD4,+,/CD8,+,T， CD25,+,Treg and NK cells were compared between the two groups， and the recent clinical efficacy was observed.,Results,2,①During the trial， there were 2 drop-out cases in the treatment group and 3 drop-out cases in the control group， and 55 cases finally completed the trial with 28 cases in the treatment group and 27 cases in the control group. ②In terms of recent efficacy comparison， the 12-month treatment efficiency of the treatment group was 42.86% and the tumor control rate was 71.42%， which were better than 33.33% and 44.44% of the control group， respectively （,P,<,0.05）. ③The levels of CD3,+,T， CD4,+,T， CD8,+,T， and CD25,+,Treg cells were lowered significantly in both groups 7 d after chemotherapy compared with those before treatment （,P,<,0.05）； and the levels of CD3,+,T， CD4,+,T， CD8,+,T， and CD25,+,Treg cells in the treatment group were higher than those in the control group 14 d and 28 d after chemotherapy （,P,<,0.05）. ④The levels of NK cells in both groups decreased 14 d after chemotherapy compared with those before treatment （,P,<,0.05）； and the levels of NK cells in the treatment group were higher than those in the control group 14 d and 28 d after chemotherapy （,P,<,0.05）.,Conclusion,2,Buyi Xiaozheng Prescription can effectively inhibit the progression of advanced ovarian cancer and positively regulate T cells and NK cells in the immune “window period” after chemotherapy， which can temporarily reverse the immune suppression in patients after chemotherapy and provide a good therapeutic environment for further immunotherapy.

关键词

卵巢癌补益消癥方化学疗法窗口期免疫调节中医药疗法

Keywords

ovarian cancerBuyi Xiaozheng Prescriptionchemotherapywindow periodimmune regulationtraditional Chinese medicine therapy

references

VOGELL A， EVANS M L. Cancer screening in women［J］. Obstet Gynecol Clin North Am， 2019， 46（3）： 485-499.

TORRE L A， TRABERT B， DESANTIS C E， et al. Ovarian cancer statistics， 2018［J］. CA Cancer J Clin， 2018， 68（4）： 284-296.

ZITVOGE L， APETOH L， GHIRINGHELLI F， et al. Immunological aspects of cancer chemotherapy［J］. Nat Rev Immunol， 2008， 8（1）： 59-73.

梁金晓，黄纯娴，林仲秋. 妇科恶性肿瘤免疫治疗进展［J］. 国际妇产科学杂志，2022， 49（2）： 191-195.

赵海云，吴小华. 免疫治疗在卵巢癌中的应用研究进展［J］. 中国癌症杂志，2020， 30（7）： 538-545.

冯勤梅，吴霞，狄文. 化疗免疫“窗口期”对卵巢癌治疗影响的实验研究［J］. 现代妇产科进展，2015， 24（4）： 255-258.

李宁，孔北华，尹如铁，等. 晚期上皮性卵巢癌一线维持治疗专家共识［J］. 现代妇产科进展，2019， 28（10）： 721-723.

周琦，吴小华，刘继红，等. 卵巢恶性肿瘤诊断与治疗指南（第四版）［J］. 中国实用妇科与产科杂志，2018， 34（7）： 739-749.

卢淮武，霍楚莹，林仲秋. 《2019NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南（第1版）》解读［J］. 中国实用妇科与产科杂志，2019， 35（5）： 536-546.

TAYLOR S G 4 th， DAVIS T E， FALKSON G，et al. PALA in advanced breast cancer. A phase Ⅱpilot study by the ECOG［J］. Am J Clin Oncol， 1982， 5（6）： 627-629.

EISENHAUER E A， THERASSE P， BOGAERTS J， et al. New response evaluation criteria in solid tumours： revised RECIST guideline（version 1.1）［J］. Eur J Cancer， 2009， 45（2）： 228-247.

李想，刘宝瑞，李茹恬. 新方向、新理念、新挑战：实体瘤内免疫治疗技术的前世今生［J］.中国肿瘤生物治疗杂志，2022， 29（10）： 863-870.

LE D T， URAM J N， WANG H， et al. PD-1 blockade in tumors with mismatch-repair deficiency［J］. N Engl J Med， 2015， 372（26）： 2509-2520.

SIEGEL R， NAISHADHAM D， JEMAL A．Cancer statistics， 2013［J］. CA Cancer J Clin， 2013， 63（1）： 11-30.

RAMAKRISHNAN R， GABRILOVICH D I. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer［J］. Cancer Immunol Immunother， 2011， 60（3）： 419-423.

BAERT T， FERRERO A， SGHOULI J， et al. The systemic treatment of recurrent ovarian cancer revisited［J］. Ann Oncol， 2021， 32（6）： 710-725.

WU X， FENG Q M， WANG Y， et al. The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy［J］. Cancer Immunol Immunother， 2010， 59（2）： 279-291.

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Based on theory of “all cold with contraction belong to the kidney” to explore the treatment of myelosuppression after chemotherapy for gastric cancer from kidney

Staged rehabilitation treatment strategy of traditional Chinese medicine after non⁃small cell lung cancer surgery

Effects of Chaihu Shugan Powder on AMPK/SIRT3 signaling pathway in rats with functional dyspepsia

A randomized， double‑blind， placebo‑controlled clinical trial on the external application of Taohong Siwu Decoction to improve the arteriovenous fistula patency during hemodialysis

Liang Linjiang's experience in treating complex anal fistula

Related Author

No data

Related Institution

Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Oncology I， Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Institute of Clinical Immunology， Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Gastroenterology Department，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Nephrology， Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

⁰